期刊
INORGANIC CHEMISTRY
卷 55, 期 9, 页码 4595-4605出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.inorgchem.6b00309
关键词
-
资金
- National Natural Science Foundation of China [21301181, 21371006, 21135006, 21321003, 21127901, 21275148]
- Institute of Chemistry, CAS [PY-2015-28]
- Beijing National Laboratory for Molecular Sciences Open Foundation [20140127]
- Anhui Provincial Natural Science Foundation [KJ2011A153]
Ruthenium-based anticancer complexes are promising antitumor agents for their low system toxicity and versatile chemical structures. Epidermal growth factor receptor (EGFR) has been found to be overexpressed in a broad range of tumor cells and is regarded as a drug target in developing novel antitumor drugs. In this work, five ruthenium(II) polypyridyl complexes containing EGFR-inhibiting 4-anilinoquinazoline pharmacophores were synthesized and characterized. These complexes showed both high EGFR-inhibiting activity and strong DNA minor groove-binding activity. In vitro antiproliferation screening demonstrated that the prepared ruthenium complexes are highly cytotoxic against a series of cancer cell lines, in particular non-small-cell lung A549 and human epidermoid carcinoma A431. Fluorescence-activated cell sorting analysis and fluorescence microscopy revealed that the most active complex, K4, induced much more late-stage cell apoptosis and necrosis than gefitinib, the first EGFR-targeting antitumor drug in clinical use. These results indicate that the ruthenium(II) polypyridyl complexes bearing EGFR-inhibiting 4-anilinoquinazolines possess highly active dual-targeting anticancer activity and are promising in developing new anticancer agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据